Day: October 12, 2020

4730-54-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

NOTPA was prepared by the reaction of 1,4,7-triazacyclonoanane (TACN) (1 mmol, 0.10 g) and acrylic acid (3 mmol, 0.16 g) in acetone (30 mL), the reaction mixture was stirred at room temperature for 2 h to give a yellowish precipitate. The resulting precipitate was filtered and washed with diethyl ether and ethanol and dried in a vacuum oven to give a light yellow powder in 80 % yield (0.27 g). FTIR (KBr, Vmax, cm-1): 3411, 3231, 2935, 2845, 2350, 1751, 1654, 1402, 1240, 621; 1H NMR (400 MHz, DMSO, delta): 12.02 (s. 3H, OH). 3.62 (s, 6H, -CH2-CH2-C=0), 3.02 (s, 6H, N-CH2-CH2-C=O), 2.36 (t, 12H, N-CH2-CH2-N): 13C NMR (100 MHz, DMSO, delta) 172.80, 60.83, 52.12, 35.65 ppm; Anal. C15H27N306 (345.0): Calc: C, 52.17; H, 7.82; N, 12.17; found: C, 52.08; H, 7.70; N, 12.04% .

4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Alshehri, Saad M.; Al-Farraj, Eida; Alhokbany, Norah; Ahamad, Tansir; Asian Journal of Chemistry; vol. 27; 6; (2015); p. 2209 – 2216;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

23616-79-7, N-Benzyl-N,N-dibutylbutan-1-aminium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Reference Example 82 A mixture of 3-[3-methoxy-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]propionaldehyde (1.79 g), sodium cyanide (0.3 g), acetic anhydride (0.62 g), benzyltributylammonium chloride (0.79 g), water (12 ml) and dichloromethane (35 ml) was stirred for 15 hours at room temperature. The organic layer was separated, which was washed with water and dried (MgSO4), followed by distilling off the solvent. The resulting oily product was subjected to column chromatography on silica gel. From the fraction eluted with ethyl acetate-hexane (1:3, v/v), was obtained 2-acetoxy-4-[3-methoxy-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]butyronitrile (2.0 g, 94%), NMR(delta ppm in CDCl3): 2.14(3H,s), 2.12-2.31(2H,m), 2.41(3H,s), 2.78(2H,t,J=8 Hz), 3.87(3H,s), 5.04(2H,s), 5.27(1H,t,J=7 Hz), 6.70(1H,dd,J=8&2 Hz), 6.71(1H,d,J=2 Hz), 7.00(1H,d,J=9 Hz), 7.42-7.47(3H,m), 7.99-8.04(2H,m), 23616-79-7

23616-79-7 N-Benzyl-N,N-dibutylbutan-1-aminium chloride 159952, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Takeda Chemical Industries, Ltd.; US5932601; (1999); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

10534-59-5, General procedure: A solution of H6buea (200 mg, 0.45 mmol) dissolved in 4 mL of anhydrous DMA was treated with solid KH (55 mg, 1.36 mmol) and stirred until gas evolution ceased. Fe(OAc)2 (79 mg, 0.45 mmol) was added to the pale yellow solution, and stirring was continued for 30 min. The resulting amber filtrate was treated with [Bu4N][OAc] (140 mg, 0.45 mmol) and stirred for 2 h, resulting in the precipitation of a white solid (305 mg) that was filtered, washed twice with Et2O, and dried under vacuum. The white solid was stirred in CH3CN for 1 h and filtered to remove KOAc (105 mg, 96%). The light yellow filtrate was concentrated to half its original volume and the slow addition of Et2O resulted in the formation of a white solid, which was then filtered, washed with Et2O, and dried under vacuum to afford 150 mg (47%) of the desired salt. [Bu4N]2[Fe(II)H22iPr]2 was prepared following a similar procedure to that of [Bu4N]2[Fe(II)H3buea]2 with H52iPr (150 mg, 0.37 mmol), KH (45 mg, 1.12 mmol), Fe(OAc)2 (66 mg, 0.37 mmol), and [Bu4N][OAc] (113 mg, 0.37 mmol). The amount of KOAc obtained was 105 mg (96% for 3 equiv) and 100 mg (42%) of [Bu4N]2[FeIIH22iPr] was isolated. FTIR (Nujol, cm-1) nu(NH) 3332, nu(CO) 1661, 1590, 1561, 1520. Repeated attempts to obtain a satisfactory elemental analysis were unsuccessful.

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Lacy, David C.; Mukherjee, Jhumpa; Lucas, Robie L.; Day, Victor W.; Borovik; Polyhedron; vol. 52; (2013); p. 261 – 267;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1119-97-7,MitMAB,as a common compound, the synthetic route is as follows.

General procedure: A 100mL round-bottom flask was equipped with a magnetic stir bar and a reflux condenser. To xylene (10.0mL), tetradecyltrimethylammonium bromide (1.1mmol) and a heterocyclic compound (1.0mmol) were added, followed bya solution of NaOH 50% (5.0 mL). The mixture was stirred at reflux temperature for 2-18 h. After completion of thereaction, the mixture was air-jet cooled to 25 C and TLC indicated the disappearance of the starting material. The reaction mix was treated with AcOEt (4 ¡Á 20 mL), and the organic phase separated and removed under reduced pressure. The residue was purified to analytical purity by column chromatography.

1119-97-7, The synthetic route of 1119-97-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Gonzalez-Gonzalez, Carlos A.; Vega, Juan Javier Mejia; Monroy, Ricardo Garcia; Gonzalez-Calderon, Davir; Corona-Becerril, David; Fuentes-Benites, Aydee; Mascarua, Joaquin Tamariz; Gonzalez-Romero, Carlos; Journal of Chemistry; vol. 2017; (2017);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

14162-95-9, 4-Bromo-2,2′-bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

In a flame dried 50-mL 3-neck flask fitted with a condenser, a mixture of anthraceneboronic acid 35-7 (522 mg, 0.985 mmol), 4-bromo-2,2?-bipyridine (154 mg, 0.657 mmol), and cesium carbonate (640 mg, 1.97 mmol) in EtOH (15 mL) and water (2 mL) was degassed by refluxing under argon stream for 75 minutes. Then Pd(OAc)2 (29.7 mg, 0.131 mmol) and PPh3 (138 mg, 0.526 mmol) were added in one portion. Refluxing under argon was continued until the reaction was complete in 90 minutes. The reaction mixture was then allowed to cool to room temperature and filtered; the solid residue was rinsed with DCM and MeOH. The filtrate was concentrated in vacuo, and the resulting residue was purified by reversed-phase flash chromatography (C18 SiO2, eluted with gradient of 0.09% HCl in MeOH). The pure product was isolated by basification of combined and concentrated fractions with solid NaHCO3 (200 mg) followed by extraction with DCM twice. The combined DCM layers were then dried over MgSO4 and concentrated in vacuo to yield product as a yellow solid (316 mg, 50%).

14162-95-9, As the paragraph descriping shows that 14162-95-9 is playing an increasingly important role.

Reference£º
Patent; Profusa, Inc.; GAMSEY, Soya; BERNAT, Viachaslau; KUTYAVIN, Alex; CLARY, Jacob William; PRADHAN, Sulolit; US2020/383; (2020); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3282-73-3,Dilauryldimethylammonium Bromide,as a common compound, the synthetic route is as follows.

A mixture of tetrakis(tributylammonium) hydroxygallium(III) naphthalocyaninetetrasulfonate (5.74 g, 3.08 mmol) and didodecyldimethylammonium bromide (5.71 g, 0.012 mol) in methanol (200 mL) was evaporated to half volume with heating under a stream of nitrogen and diluted with water (100 mL). The solid was filtered off and washed with hot water (3¡Á250 mL) and hot acetone/water (50:50, 3¡Á250 mL) and allowed to dry. The solid was then washed further with toluene (2¡Á250 mL) and boiling hexane (250 mL) and dried to give the product as a green powder (7.32 g, 90%).1H NMR (d6-DMSO) delta 0.86 (24H, t, J=6.6 Hz); 1.25 (144H, m); 1.62 (16H, m); 3.20 (16H, m); 4.25 (24H, s); 7.9-11.1 (20H, m).1H NMR (d6-DMSO): delta -0.46 (1H, s); 0.83 (24H, t, J=6.6 Hz); 1.25 (144H, m); 1.60 (16H, m); 3.20 (16H, m); 4.25 (24H, s); 7.9-11.1 (20H, m).UV-Vis-NIR (DMSO): lambdamax 790, 704, 342 nm.

3282-73-3, As the paragraph descriping shows that 3282-73-3 is playing an increasingly important role.

Reference£º
Patent; Silverbrook Research Pty Ltd; US2009/35533; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13040-77-2,6-Chloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

The reaction was performed under argon. Substituted azole (excess) and potassium tert-butoxide were dissolved at RT in dry and degassed DMSO. An exothermic reaction occurred. The mixture was stirred for 10 min to allow the reaction to finish and cool. Then, a substituted halopyridine was added. The reaction mixture was stirred for 24 h at 140C to give a suspension. It was cooled to RT. Water (50mL) was added: the product precipitated on stirring/sonication. The solid was filtered, washed with water, and extracted with dichloromethane and water. The organic layer was washed with water to extract DMSO. Purification by chromatography on silica (20g) removed the starting materials and by-products on elution with 0-0.4% CH3OH in CH2Cl2, and provided the pure product on elution with 0.4-1.0% CH3OH in CH2Cl2. Anal. Calc. for C15H14N4 (MW 250.30): C, 71.98; H, 5.64; N, 22.38. Found: C, 72.04; H, 5.48; N, 22.48%.

13040-77-2, 13040-77-2 6-Chloro-2,2′-bipyridine 11116850, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Shavaleev, Nail M.; Kessler, Florian; Graetzel, Michael; Nazeeruddin, Mohammad K.; Inorganica Chimica Acta; vol. 407; (2013); p. 261 – 268;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5,4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1,4,7-Triazacyclononane (41 mg, 0.32 mmol, 1 equiv.) and6-(bromomethyl)-2-methyl-3-nitropyridine. (258 mg, 1.12 mmol, 3.5 equiv.) were dissolved in 8 mL of dry acetonitrile followed by addition of triethylamine (180 .iL, 1.29 mmol, 4 equiv.). The reaction mixture was stirred at 50 C for 24 hours under argon. Upon completion of the reaction, solvent was removed in vacuo producing a brown oily residue. The crudeproduct was purified by reversed-phase HPLC using a gradient of solvent B from 30% to70% in solvent A over 40 minutes. ESI-MS analyses of fractions with retention time tR = 21minute confirmed product iv. These fractions were combined and solvent was removed bylyophilization producing iv in the form of TFA salt. Yield: 80 mg, 63 .imol, 20%. ?H NMR,500 MHz (CD3OD, ppm): oe = 8.35 d (3H, Ar, J = 9 Hz), 7.55 d (3H, Ar, J = 9 Hz), 4.32 s(6H, 3CH2), 3.23 m (12H, 6CH2), 2.78 s (9H, 3CH3). ?3C NMR, 75 MHz (CD3OD, ppm): oe =160.60, 154.51, 146.59, 134.91, 123.40, 60.07, 50.74, 23.92. High-resolution ESI-MS (mlz):[M+H], calculated: 580.2627, found: 580.2691.

As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.

Reference£º
Patent; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK UNIVERSITY AT BUFFALO; HEALTH RESEARCH, INC.; MORROW, Janet, R.; TSITOVICH, Pavel, B.; DORAZIO, Sarina, J.; OLATUNDE, Abiola, O.; SNYDER, Eric, M.; SPERNYAK, Joseph, A.; BURNS, Patrick; BOND, Christopher, J.; WO2015/38943; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

111795-43-8, (R)-(+)-3,3′-Dibromo-1,1′-bi-2-naphthol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Unless stated otherwise, the reaction was performed in a flamedriedflask. A mixture of BOPHY 1a (25 mg, 0.09 mmol, 1 mol equiv.)and aluminum chloride (59 mg, 0.44 mmol, 5 mol equiv.) in dry CH2Cl2(DCM, 5 mL) was refluxed under argon atmosphere until reactioncompletion (reaction monitored by TLC). The mixture was cooled downto room temperature and, then, a solution of (R)-BINOL ((R)-1,1?-binapht-2-ol, 101 mg, 0.35 mmol, 4 mol equiv.) in anhydrous acetonitrile(2 mL) was added dropwise. The resulting mixture was stirred at r.t. foradditional 6 h. After filtration and solvent evaporation under reducedpressure, the obtained residue was purified by flash chromatography(hexane/DCM 7:3) to afford 1b (24 mg, 35%) as a yellow solid.

111795-43-8, As the paragraph descriping shows that 111795-43-8 is playing an increasingly important role.

Reference£º
Article; Sola-Llano; Jimenez; Avellanal-Zaballa; Johnson; Cabreros; Moreno; Maroto; Muller; Banuelos; Cerdan; Garcia-Moreno; Moya, S. de la; Dyes and Pigments; vol. 170; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI